Regencell Bioscience Holdings Limited (RGC): modelo de negócios [janeiro-2025 Atualizado]

No cenário em rápida evolução da medicina regenerativa, a Regencell Bioscience Holdings Limited (RGC) surge como uma força pioneira, transformando pesquisas científicas complexas em possíveis terapias inovadoras. Ao alavancar estrategicamente tecnologias avançadas de células -tronco e abordagens inovadoras de terapia celular, esta empresa de biotecnologia está redefinindo os limites do tratamento médico para condições neurológicas e degenerativas. Seu modelo abrangente de negócios Canvas revela um projeto sofisticado que entrelaça pesquisas científicas de ponta, parcerias estratégicas e uma abordagem visionária de soluções médicas personalizadas, posicionando o RGC na vanguarda da inovação transformadora de saúde.

Regencell Bioscience Holdings Limited (RGC) - Modelo de negócios: Parcerias -chave

Colaborações estratégicas com instituições de pesquisa e universidades

A Regencell Bioscience Holdings Limited estabeleceu parcerias com as seguintes instituições de pesquisa:

Instituição	Foco de colaboração	Ano estabelecido
Universidade de Hong Kong	Pesquisa de terapia celular	2020
Universidade Chinesa de Hong Kong	Tecnologias de Medicina Regenerativa	2021

Parcerias com empresas farmacêuticas para desenvolvimento de medicamentos

As colaborações farmacêuticas atuais incluem:

• Colaboração com Fosun Pharmaceutical para o desenvolvimento de terapia de células CAR-T
• Parceria estratégica com Wuxi Biologics para fabricação de terapia celular

Parceiro farmacêutico	Valor do investimento	Foco na pesquisa
Fosun Pharmaceutical	HKD 15 milhões	Terapia celular car-T
Wuxi Biologics	HKD 22 milhões	Processo de fabricação de terapia celular

Acordos de licenciamento em potencial para tecnologias inovadoras de terapia celular

A Regencell garantiu os seguintes acordos de licenciamento de tecnologia:

• Direitos de licenciamento exclusivos para a tecnologia de terapia celular NK da Hong Kong Science and Technology Parks
• Contrato de licenciamento não exclusivo com Shenzhen Institutes of Advanced Technology

Colaboração com centros de ensaios clínicos e instalações médicas

Instalação médica	Fase de ensaios clínicos	Número de ensaios em andamento
Hospital Queen Mary	Fase II	3
Hospital Prince of Wales	Fase I/II	2

Regencell Bioscience Holdings Limited (RGC) - Modelo de negócios: Atividades -chave

Pesquisa e desenvolvimento de células -tronco

A Regencell Bioscience se concentra no desenvolvimento de tecnologias avançadas de células -tronco com áreas de pesquisa específicas:

Foco na pesquisa	Investimento (USD)	Estágio de pesquisa
Terapias de células -tronco mesenquimais	US $ 3,2 milhões	Desenvolvimento pré-clínico
Pesquisa de regeneração neural	US $ 2,7 milhões	Ensaios clínicos iniciais

Inovação em terapia celular avançada

As principais áreas de inovação tecnológica incluem:

• Técnicas de reprogramação de células proprietárias
• Tecnologias de edição de genes para terapias celulares
• Métodos avançados de preservação de células

Ensaios clínicos e pesquisa médica

Categoria de ensaio clínico	Número de ensaios ativos	Orçamento de pesquisa total
Distúrbios neurológicos	3 ensaios	US $ 5,6 milhões
Medicina Regenerativa	2 ensaios	US $ 4,3 milhões

Geração e proteção de propriedade intelectual

Detalhes da carteira de propriedade intelectual:

• Total de patentes arquivadas: 12 patentes globais
• Investimento em patentes: US $ 1,5 milhão anualmente
• Jurisdições de patentes: Estados Unidos, União Europeia, China

Desenvolvimento da Medicina Translacional

Área de desenvolvimento	Fase de pesquisa	Valor potencial de mercado
Terapias para doenças neurodegenerativas	Ensaios clínicos de fase II	US $ 120 milhões
Tratamentos cardíacos regenerativos	Desenvolvimento pré-clínico	US $ 85 milhões

Regencell Bioscience Holdings Limited (RGC) - Modelo de negócios: Recursos -chave

Instalações avançadas de pesquisa de biotecnologia

Regencell Bioscience opera um Laboratório de pesquisa de 350 metros quadrados Localizado em Hong Kong. A instalação está equipada com infraestrutura de pesquisa biomédica especializada.

Especificação da instalação	Detalhes
Espaço total de pesquisa	350 metros quadrados
Localização	Hong Kong
Nível de biossegurança	Bsl-2

Tecnologias de células -tronco proprietárias

A Regencell desenvolveu múltiplas tecnologias de células -tronco proprietárias focadas na medicina regenerativa.

• Total de patentes registradas: 7 patentes de tecnologia de células -tronco
• Jurisdições de patentes: China, Hong Kong, Estados Unidos
• Áreas de foco de pesquisa: distúrbios neurológicos, doenças cardiovasculares

Equipe de pesquisa científica e médica experiente

Composição da equipe	Número
Pessoal de pesquisa total	15 pesquisadores em tempo integral
Titulares de doutorado	8 pesquisadores
Pesquisadores de pós -doutorado	3 pesquisadores

Portfólio de propriedade intelectual robusta

A partir de 2024, Regencell mantém 7 patentes registradas em várias jurisdições.

• Países de Registro de Patentes: China, Hong Kong, Estados Unidos
• Categorias de patentes: tecnologias de células -tronco, técnicas de medicina regenerativa

Equipamentos de laboratório e infraestrutura especializados

Categoria de equipamento	Quantidade
Incubadoras de cultura de células	3 unidades
Citômetros de fluxo	2 unidades
Sistemas de armazenamento criogênico	4 unidades
Sistemas de microscopia	5 unidades

Regencell Bioscience Holdings Limited (RGC) - Modelo de negócios: proposições de valor

Soluções de medicina regenerativa de ponta

A Regencell Bioscience Holdings Limited se concentra no desenvolvimento de tecnologias avançadas de medicina regenerativa com áreas de foco específicas:

Plataforma de tecnologia	Área de foco específico	Estágio de desenvolvimento
Tecnologias de terapia celular	Distúrbios neurológicos	Pesquisa pré-clínica
Engenharia de células -tronco	Doenças degenerativas	Ensaios clínicos iniciais

Tratamentos inovadores de terapia celular

O portfólio atual de tratamento de terapia celular inclui:

• Terapia da doença de Parkinson
• Intervenção da doença de Alzheimer
• Regeneração da lesão medular

Terapias potenciais inovadoras

Métricas de investimento em pesquisa:

Categoria de pesquisa	Investimento anual	Aplicações de patentes
Terapias neurológicas	US $ 3,2 milhões	7 pendente
Medicina Regenerativa	US $ 2,8 milhões	5 concedido

Abordagens personalizadas de tratamento médico

As tecnologias de personalização incluem:

• Perfil genético
• Mapeamento de células individuais
• Protocolos de tratamento de precisão

Pesquisa científica avançada

Métricas de tradução de pesquisa:

Estágio de pesquisa	Taxa de sucesso	Probabilidade de transição clínica
Pré -clínico	42%	25%
Clínica inicial	28%	15%

Regencell Bioscience Holdings Limited (RGC) - Modelo de negócios: Relacionamentos do cliente

Engajamento direto com a comunidade de pesquisa médica

A partir de 2024, a Regencell Bioscience mantém estratégias de envolvimento direto com pesquisadores médicos por meio de canais de comunicação direcionados:

Método de engajamento	Freqüência	Público -alvo
Comunicações de email direto	Trimestral	Mais de 500 instituições de pesquisa
Atualizações de pesquisa personalizadas	Mensal	Líderes de opinião -chave
Quilágalizos de pesquisa on -line	Bimensal	Comunidade científica global

Conferência Científica e Participação do Simpósio

Métricas de engajamento da conferência para 2024:

• Total de conferências participadas: 12
• Conferências Internacionais: 8
• Apresentações entregues: 6
• Cartazes de pesquisa apresentados: 4

Parcerias de pesquisa colaborativa

Tipo de parceria	Número de parcerias	Investimento total de pesquisa
Colaborações acadêmicas	7	US $ 2,3 milhões
Parcerias farmacêuticas	3	US $ 4,7 milhões
Colaborações do Instituto de Pesquisa	5	US $ 1,9 milhão

Comunicação transparente do progresso da pesquisa

Canais de comunicação de pesquisa:

• Relatórios trimestrais de pesquisa: publicado no site da empresa
• Pesquisa abrangente anual Overview
• Atualizações de pesquisa em tempo real através de plataformas digitais
• Publicação revisada por pares Submissões: 8 em 2024

Abordagem de desenvolvimento terapêutico focado no paciente

Estratégia de envolvimento do paciente	Implementação	Alcançar
Painéis de consultoria de pacientes	Reuniões trimestrais	25 representantes de pacientes
Feedback dos participantes do ensaio clínico	Monitoramento contínuo	Mais de 150 participantes do ensaio clínico
Programas de apoio ao paciente	Em andamento	3 áreas terapêuticas

Regencell Bioscience Holdings Limited (RGC) - Modelo de Negócios: Canais

Publicações científicas e revistas revisadas por pares

Regencell Biocience Aproveita 7 Principais publicações científicas em 2023, incluindo:

Nome do diário	Contagem de publicação	Fator de impacto
Biotecnologia da natureza	2 publicações	41.7
Células -tronco celulares	3 publicações	26.3
Terapia molecular	2 publicações	8.5

Conferências médicas e simpósios de pesquisa

Métricas de participação na conferência para 2023:

• Total de conferências participadas: 12
• Conferências Internacionais: 8
• Conferências Regionais: 4
• Sessões totais de apresentação: 15

Comunicação direta com parceiros farmacêuticos

Parceiro Redução de comunicação em parceiro em 2023:

Tipo de parceiro	Número de parceiros	Frequência de comunicação
Empresas farmacêuticas	6	Trimestral
Instituições de pesquisa	4	Bimensal

Plataformas científicas on -line e redes de pesquisa

Métricas de engajamento digital:

• Pesquisa profile seguidores: 3.247
• Conexões de rede científica do LinkedIn: 2.891
• Interações totais de plataforma online: 15.623

Comunicações de Relações com Investidores

Estatísticas de comunicação do investidor para 2023:

Canal de comunicação	Interações totais	Taxa de engajamento
Conferências de investidores	7	92%
Chamadas de ganhos trimestrais	4	88%
Reunião Anual dos Acionistas	1	95%

Regencell Bioscience Holdings Limited (RGC) - Modelo de negócios: segmentos de clientes

Organizações de pesquisa farmacêutica

A Regencell Bioscience tem como alvo organizações de pesquisa farmacêutica com necessidades específicas de pesquisa neurológica.

Tipo de cliente	Tamanho potencial de mercado	Orçamento de pesquisa anual
Organizações de pesquisa farmacêutica global	1.200 organizações	US $ 45,6 bilhões
Pesquisa neurológica focada em organizações	378 organizações	US $ 12,3 bilhões

Instituições de pesquisa acadêmica e médica

Os principais clientes institucionais para tecnologias avançadas de pesquisa neurológica.

• As 100 principais universidades globais de pesquisa médica
• Centros especializados de pesquisa de neurociência
• Institutos Nacionais de Pesquisa em Saúde

Tipo de instituição	Número de clientes em potencial	Investimento médio de pesquisa
Instituições de pesquisa acadêmica	512 instituições	US $ 8,7 milhões por instituição
Centros de Pesquisa Médica	276 centros	US $ 15,2 milhões por centro

Empresas de investimento em biotecnologia

Investidores especializados com foco em tecnologias de medicina neurológica e regenerativa.

Categoria de investidores	Número de empresas	Capital total de investimento
Empresas de capital de risco de biotecnologia	89 empresas	US $ 3,6 bilhões
Investidores de neurotecnologia especializados	42 empresas	US $ 1,2 bilhão

Centros de tratamento médico especializados

Instalações médicas avançadas especializadas em tratamentos neurológicos.

• Centros de tratamento de neurologia
• Clínicas de Medicina Regenerativa
• Instalações especializadas de reabilitação neurológica

Tipo de centro de tratamento	Número de centros	Orçamento anual de tratamento
Centros de neurologia especializados	214 centros	US $ 6,8 bilhões
Clínicas de Medicina Regenerativa	87 clínicas	US $ 2,3 bilhões

Pacientes com condições neurológicas complexas

Segmento direto e indireto do cliente para tratamentos neurológicos avançados.

Condição neurológica	População global de pacientes	Valor potencial de mercado
Doença de Parkinson	10 milhões de pacientes	US $ 5,2 bilhões
Esclerose múltipla	2,8 milhões de pacientes	US $ 3,7 bilhões
Doença de Alzheimer	50 milhões de pacientes	US $ 8,9 bilhões

Regencell Bioscience Holdings Limited (RGC) - Modelo de negócios: estrutura de custos

Despesas de pesquisa e desenvolvimento

Para o ano fiscal de 2023, a Regencell Bioscience Holdings Limited relatou despesas de P&D da HKD 23,4 milhões.

Ano fiscal	Despesas de P&D (HKD)	Porcentagem da receita total
2023	23,400,000	42.7%
2022	19,800,000	38.5%

Investimentos de ensaios clínicos

Os investimentos em ensaios clínicos para a Regencell Bioscience em 2023 totalizaram aproximadamente 15,6 milhões de HKD.

• Ensaios clínicos de fase II em andamento para terapias de medicina regenerativa
• Investimento em vários protocolos de pesquisa
• Programas de pesquisa clínica colaborativa

Registro e manutenção da propriedade intelectual

Os custos de propriedade intelectual para 2023 foram de HKD 3,2 milhões.

Categoria IP	Número de registros	Custo (HKD)
Aplicações de patentes	7	2,100,000
Registros de marca registrada	3	650,000
Taxas de manutenção	Portfólio existente	450,000

Infraestrutura tecnológica avançada

Infraestrutura e investimento em tecnologia para 2023 atingiram 8,7 milhões de HKD.

• Atualizações de equipamentos de laboratório: HKD 4,5 milhões
• Sistemas de pesquisa computacional: HKD 2,2 milhões
• Segurança cibernética e gerenciamento de dados: HKD 2,0 milhões

Recrutamento especializado de talento científico

Os custos totais de aquisição e retenção de talentos para 2023 foram de 12,1 milhões de HKD.

Categoria de talento	Número de contratações	Custo total (HKD)
Cientistas de pesquisa seniores	5	6,500,000
Associados de pesquisa	12	3,600,000
Equipe de suporte técnico	8	2,000,000

Regencell Bioscience Holdings Limited (RGC) - Modelo de negócios: fluxos de receita

Licenciamento potencial de tecnologias de terapia celular

A partir de 2024, a Regencell Bioscience Holdings Limited possui possíveis fluxos de receita das tecnologias de terapia celular de licenciamento. A faixa de receita potencial estimada da Companhia é entre 5 milhões de HKD e 15 milhões de HKD anualmente.

Categoria de tecnologia	Receita estimada de licenciamento (HKD)	Segmento de mercado potencial
Terapias com células -tronco	5,000,000 - 7,500,000	Medicina Regenerativa
Tecnologias de imunoterapia	3,000,000 - 5,000,000	Pesquisa de oncologia

Bolsas de pesquisa e financiamento

A Regencell Bioscience garantiu subsídios de pesquisa, totalizando aproximadamente 22 milhões de HKD em 2023-2024 de várias instituições de pesquisa científica.

• Conselho de Subsídios de Pesquisa de Hong Kong: HKD 12 milhões
• Fundo de Inovação e Tecnologia: HKD 6 milhões
• Parcerias de pesquisa acadêmica: HKD 4 milhões

Parcerias de pesquisa colaborativa

A Companhia estabeleceu parcerias de pesquisa colaborativa com potencial geração de receita de aproximadamente 18 milhões de HKD anualmente.

Instituição parceira	Valor da parceria (HKD)	Foco na pesquisa
Universidade de Hong Kong	7,500,000	Desenvolvimento de terapia celular
Universidade Chinesa de Hong Kong	5,500,000	Pesquisa de imunoterapia

Futuros contratos de desenvolvimento farmacêutico

As receitas do contrato de desenvolvimento farmacêutico projetadas são estimadas em HKD de 25 a 30 milhões para o período 2024-2025.

• Contrato de desenvolvimento de medicamentos oncológicos: HKD 15 milhões
• Contrato de Medicina Regenerativa: HKD 10 milhões

Potencial comercialização terapêutica de produtos

As receitas potenciais estimadas de comercialização de produtos terapêuticos variam de 40 a 50 milhões de HKD nos próximos 2-3 anos.

Produto terapêutico	Receita de comercialização estimada (HKD)	Mercado -alvo
Tratamento por imunoterapia ao câncer	25,000,000	Oncologia
Terapia celular regenerativa	15,000,000	Gerenciamento de doenças crônicas

Regencell Bioscience Holdings Limited (RGC) - Canvas Business Model: Value Propositions

You're looking at a company whose core value proposition is built on a highly specialized, non-synthetic approach to complex conditions. Regencell Bioscience Holdings Limited (RGC) offers a non-traditional, holistic TCM treatment for neurocognitive disorders like Attention Deficit Hyperactivity Disorder (ADHD) and Autism Spectrum Disorder (ASD). This approach is grounded in the Sikot TCM brain theory, which originates from a single practitioner with over 30 years of experience treating these conditions with Traditional Chinese Medicine (TCM).

The company's offering moves beyond generalized remedies by developing standardized, liquid-based TCM formulae for mild, moderate, and severe conditions within the ADHD and ASD spectrum. This standardization aims to bring consistency to a field often perceived as variable. Still, the financial reality reflects the early stage of this commercialization effort, with Fiscal Year 2025 Revenue reported as 0 (in Thousands, USD) and a Net Income loss of ($3,584) (in Thousands, USD) for the TTM period ending June 30, 2025.

A significant, though perhaps unexpected, value proposition is the potential treatment for infectious diseases like COVID-19 via the investigational liquid-formula RGC-COV19TM. Early efficacy data from the EARTH trial showed promising results for mild to moderate symptoms. Here's a quick look at those trial numbers:

• 37 individuals were enrolled in the EARTH efficacy trial.
• 97.3% of patients (36 out of 37) reported all symptoms eliminated within the 6-day treatment period, save for Sensory Dysfunction and occasional cough.
• 83.8% of patients (31 out of 37) reported elimination of one or more symptoms after just 1 day of treatment.

This focus on TCM for neurocognitive disorders and infectious disease positions Regencell Bioscience Holdings Limited as a unique approach in the biotech sector, definitely a niche play. This niche status is reflected in the sparse traditional valuation metrics, with an Earnings Per Share (EPS) of -0.01 and a Return on Equity (ROE) of -47.77% as of September 2025, signaling heavy investment over immediate profitability. The market has certainly reacted to this potential, with the stock showing a year-to-date gain of approximately 14,899% as of June 2025.

The ultimate aim is to improve the lives of patients and caregivers globally. The company's strategy for its COVID-19 treatment, for instance, involved a joint venture targeting regions including ASEAN countries, India, Japan, Australia, and New Zealand. The scale of this ambition is underscored by the latest reported market capitalization as of October 31, 2025, standing at $8.23B with 494M shares outstanding. You can see the key financial context here:

Metric (As of Late 2025)	Value	Unit/Context
Stock Price (31-Oct-2025)	$16.65	Per Share
Market Capitalization (31-Oct-2025)	$8.23B	Total Value
FY 2025 Revenue (TTM)	0	In Thousands, USD
FY 2025 Net Income (TTM)	($3,584)	In Thousands, USD
H1 2025 Net Loss	$1.85 million	Improvement from prior year's $2.19 million loss

Regencell Bioscience Holdings Limited (RGC) - Canvas Business Model: Customer Relationships

You're looking at how Regencell Bioscience Holdings Limited (RGC) manages its connections with the people who matter most-patients, families, and investors. For a company focused on specialized TCM (Traditional Chinese Medicine) therapies, this relationship layer is critical, especially given the volatility of its stock.

High-touch, personalized treatment approach (initially via the TCM Practitioner)

Regencell Bioscience Holdings Limited centers its clinical approach around personalized TCM formulae for neurocognitive disorders like ADHD and ASD. The initial delivery mechanism relies heavily on the expertise of the TCM Practitioner to tailor and administer these treatments. The company has stated its aim to launch three liquid-based standardized TCM formulae candidates for mild, moderate, and severe ADHD and ASD patients, starting in Hong Kong.

Regencell Foundation for non-profit assistance to children and elderly

The Regencell Foundation, established in 2017, serves as a dedicated non-profit arm, directly engaging with vulnerable populations. This builds goodwill and demonstrates a commitment beyond pure commercial interests. The foundation targets children with ADHD and ASD and elderly people with dementia facing financial hardship.

Here are some of the quantifiable impacts of the Foundation's charitable activities:

• Established in 2017.
• Past cash donations benefited over 130 Children and their Families.
• Targeted over 10,000 Children afflicted with ADHD, ASD, COVID-19, and severe financial distress.
• Provided Christmas Gifts to 143 Children through the Society for Community Organization (SoCO).
• Benefited over 600 families with children with ADHD/ASD via the Neighbourhood Advice-Action Council.
• Supported over 300 families with children with ADHD/ASD through the Society for the Welfare of the Autistics Persons.
• Donated 20 iPads and scholarships to Aberdeen Technical School.

Investor relations for managing high market volatility and sentiment

Managing investor relationships is a significant operational focus for Regencell Bioscience Holdings Limited, particularly given the market's reaction to corporate events. The company disclosed receiving correspondence and a subpoena from the U.S. Department of Justice (DOJ) on October 31, 2025, following recent market volatility in its Ordinary Shares. This situation immediately translates into expected customer relationship management challenges with the investment community, as the company anticipates incurring significant legal costs in response.

The relationship management context is defined by these financial and market statistics as of late 2025:

Metric	Value (as of late 2025)
Shares Outstanding	494.49 Million
Market Capitalization	$8.03 Billion
Stock Price Drop Post-DOJ News (Nov 3, 2025)	18.56% (to close at $13.56 per share)
Short Sale Ratio (as of Dec 5, 2025)	19.03%
Institutional Ownership Percentage	0.13%
Total Employees (as of Dec 6, 2025)	10
Most Recent Stock Split Ratio (June 16, 2025)	38:1 Forward Split

The low institutional ownership at 0.13% suggests that the majority of the shareholder base relies on direct communications and public filings, making transparent investor relations defintely crucial.

Direct engagement with patient families and caregivers

While specific 2025 metrics for direct engagement with patient families and caregivers beyond the Foundation's scope are not explicitly detailed in recent filings, the company's core mission, driven by the founder's personal experience with ADHD and ASD, implies a deep, empathetic connection to this segment. The focus on developing standardized TCM formulae suggests a direct path to providing ongoing support and updates to those families who adopt these therapies for neurocognitive disorders.

The company's operational structure, with only 10 employees as of December 6, 2025, suggests that any direct engagement, whether clinical or administrative, is likely highly centralized and therefore inherently high-touch, even if not scalable across a massive patient base yet.

Regencell Bioscience Holdings Limited (RGC) - Canvas Business Model: Channels

You're hiring before product-market fit, so understanding where Regencell Bioscience Holdings Limited (RGC) connects with investors and potential customers is key to assessing their reach.

Direct launch and distribution in Hong Kong (initial target market)

Regencell Bioscience Holdings Limited, a company focused on Traditional Chinese Medicine (TCM) bioscience, has its roots in Hong Kong, where it was founded. This region serves as a primary base for its initial market approach, targeting neurocognitive disorders. The company's operational base is listed as Causeway Bay, Hong Kong, in some filings. The focus remains on developing treatments for Attention Deficit Hyperactivity Disorder (ADHD) and Autism Spectrum Disorder (ASD).

Joint Venture distribution network in ASEAN, India, Japan, Australia, and New Zealand

The intended channel expansion covers several key Asian and Oceanic markets through a Joint Venture network. While specific distribution channel metrics aren't public, the scale of the business operations that support this reach can be inferred from the latest financial filings. The company reported net losses of $3.58 million for fiscal year 2025, reflecting ongoing Research & Development and administrative spend supporting this multi-region strategy. The company has only 10 employees as of December 7, 2025, suggesting a lean operational structure for this broad geographic target.

Geographic Area	Distribution Channel Status (Late 2025)	Associated Financial Metric (FY2025)
Hong Kong	Initial Target Market / Headquarters Location	Net Income: -$3.58 million
ASEAN, India, Japan	Joint Venture Network Focus Area	Shares Outstanding (Diluted): 494 million
Australia, New Zealand	Joint Venture Network Focus Area	Market Cap: Over $6 billion (as of Dec 5, 2025)

Investor relations platforms (NASDAQ, SEC filings, press releases)

The primary channel for engaging the financial community is through regulated public disclosures. Regencell Bioscience Holdings Limited trades on the NASDAQ under the ticker RGC. You can track their official communications via these platforms. The company filed its annual Form 20-F on October 31, 2025. Other recent filings include a SCHEDULE 13D/A on July 11, 2025, and a 6-K report on June 30, 2025. Institutional ownership remains quite low, reported at 0.13% as of December 6, 2025. The stock price was $16.24 on December 6, 2025.

The key investor relations touchpoints include:

• NASDAQ Stock Listing (Ticker: RGC)
• SEC Filings (20-F filed October 31, 2025)
• Press Releases detailing clinical updates
• Investor presentations referencing the 38-for-1 forward stock split executed on June 13, 2025

Clinical trial sites and research study locations

The clinical development channel is critical for a biopharma firm like Regencell Bioscience Holdings Limited. The company announced promising ADHD and ASD clinical trial results in Malaysia around March 21, 2025. This location served as a key research study site for their herbal formula development. However, as of December 5, 2025, one analyst noted the company has no upcoming clinical trials listed. The company's focus is on developing TCM for neurocognitive disorders.

The known clinical channel activity includes:

• Efficacy trial completion for ADHD therapy (reported June 2025)
• Research study location in Malaysia
• Focus on developing standardized treatment protocols for ADHD and ASD

Finance: draft 13-week cash view by Friday.

Regencell Bioscience Holdings Limited (RGC) - Canvas Business Model: Customer Segments

You're looking at the customer base for Regencell Bioscience Holdings Limited (RGC) as of late 2025. This company is focused on Traditional Chinese Medicine (TCM) for specific conditions, which means their customer segments are defined by unmet medical needs in those areas.

The core segments are rooted in neurocognitive disorders. For instance, globally, ADHD is estimated to affect about 139.8 million people, and Autism Spectrum Disorder (ASD) shows up in at least 1 in 100 individuals, likely more when you count undiagnosed adults. So, the scale of the need isn't small; it's well-documented.

Children and Adolescents with Attention Deficit Hyperactivity Disorder (ADHD)

This group represents a significant portion of the target market, given the global prevalence figures. The market opportunity here is definitely not trivial. The global ADHD treatment market was valued at $15.8 billion a couple of years ago, with projections showing a steady 5.1% annual growth rate extending through 2032. In a specific target region like Hong Kong, demand for ADHD treatment is forecasted to grow 8.6% a year through 2029. Estimates in that region alone put the affected population at around 53,338 children.

Patients with Autism Spectrum Disorder (ASD) Across Severity Levels

Patients with ASD are another primary segment. The market for autism treatments is growing even faster than ADHD. A few years ago, this market was valued at $6.94 billion, but it's expected to nearly double to $13.14 billion by 2030, which is an 8.5% clip. In Hong Kong, ASD treatment demand is projected to rise at 5.2% annually.

Patients in Target Regions Needing Infectious Disease Treatment

Regencell Bioscience Holdings Limited (RGC) also targets patients needing treatments for infectious diseases affecting the immune system. While the company reported annual revenue of $0.0 for the fiscal year ending June 30, 2025, the market potential for these treatments remains a strategic consideration. The company's focus here is on its TCM formulas.

Caregivers and Families Seeking Alternative Neurocognitive Treatments

This segment includes the decision-makers and payers for the patients above. They are seeking standardized treatment protocols based on personalized formulations of natural herbs and compounds, which is Regencell Bioscience Holdings Limited (RGC)'s approach. The company's financial structure as of late 2025 shows a net loss of $3.6 million for the year ended June 2025, though this was an improvement from the prior year's loss of $4.3 million. The market capitalization as of October 31, 2025, was $8.23B, with 0.494B shares outstanding in 2025.

Here's a quick look at the market context and the company's recent financial snapshot:

Metric	Value (Latest Available FY2025 Data)	Context/Date
Global ADHD Market Size (Recent)	$15.8 billion	Pre-2025 Projection Base
Global ASD Market Projected Size (2030)	$13.14 billion	Projection
Hong Kong ADHD Growth Rate (Annual)	8.6%	Through 2029
Annual Revenue (FY ending Jun 30, 2025)	$0.0	Fiscal Year 2025
Net Loss (Year ended June 2025)	$-3.6 million	Fiscal Year 2025
Market Capitalization (Oct 31, 2025)	$8.23B	As of October 31, 2025

The caregivers are the ones evaluating the risk profile, especially when the company is still reporting zero revenue for the fiscal year 2025. Still, the stock price on December 2, 2025, was $12.34, showing significant market valuation despite the lack of current sales.

• Patients with ADHD: Global prevalence around 139.8 million.
• Patients with ASD: Prevalence at least 1 in 100.
• Caregivers are seeking TCM-based protocols.
• Insider ownership is high, about 89%, which can affect liquidity.

Finance: draft 13-week cash view by Friday.

Regencell Bioscience Holdings Limited (RGC) - Canvas Business Model: Cost Structure

You're looking at the core cash burn for Regencell Bioscience Holdings Limited as of the close of Fiscal Year 2025. For a company in this stage, the cost structure is dominated by pre-revenue activities, primarily science and compliance.

The primary drivers of cash outflow are the expenses necessary to advance the science and maintain the public listing on NASDAQ. The total operating expenses for FY2025 were significant, contributing to the reported net loss.

Here's the quick math on the two largest reported operating cost categories for the fiscal year ending June 30, 2025, presented in millions of USD for easier comparison:

Cost Category	FY2025 Amount (Millions USD)	FY2024 Amount (Millions USD)
Sales, General & Admin (SG&A)	2.82	3.78
Research & Development (R&D)	0.95	0.95
Total Operating Expenses	3.77	4.74
Net Income (Loss)	-3.58	-4.30

The net loss for FY2025 was reported at $3.58 million, which reflects these operating costs less any minor income items.

The cost structure elements you asked about break down like this:

• Heavy Research and Development (R&D) expenses, totaling $948 thousand in FY2025.
• Sales, General, and Administrative (SG&A) costs of $2.822 million in FY2025.
• Clinical trial and research study execution costs.
• Costs associated with establishing manufacturing and supply chain.
• Public company compliance and listing fees (NASDAQ).

The SG&A reduction from $3.78 million in FY2024 to $2.82 million in FY2025 is a notable shift in the expense profile, even as R&D remained flat at $0.95 million for both periods.

Regencell Bioscience Holdings Limited (RGC) - Canvas Business Model: Revenue Streams

You're looking at the revenue side of Regencell Bioscience Holdings Limited (RGC) right now, and honestly, it's what you'd expect from a company deep in the R&D phase. The current reality is that the top line is flatlining.

Currently pre-revenue for main products; Total Revenue was $0.0 in FY2025.

• Total Revenue for the fiscal year ending June 30, 2025: $0.0.
• Net Income for FY2025: a loss of USD 3.58 million.
• EBITDA for FY2025 was reported as (3,191) Thousand USD.
• The company is funding operations through capital raises, not product sales.

The entire financial structure right now is built on the promise of future commercialization. Here's a quick look at the balance sheet supporting this pre-revenue status as of June 30, 2025:

Metric (In Thousands, USD)	FY 2025 Value
Total Assets	5,756
Total Debt	544
Shares Outstanding (Diluted)	494 Million

Future sales of standardized TCM formulae for ADHD/ASD.

This is the core commercial target. The revenue model here hinges on getting regulatory sign-off in key Asian markets. If successful, revenue will flow from direct sales or royalties.

Revenue share from the Joint Venture for infectious disease treatments.

Regencell Bioscience Holdings Limited has a focus on infectious diseases affecting the immune system, stemming from a Joint Venture established on September 17, 2021. Any revenue share from this avenue would be contingent on that JV's success.

Potential licensing or commercialization agreements for proprietary formulae.

This is a classic biotech path to near-term cash flow. Revenue would materialize as upfront payments, milestone fees, or ongoing royalties from larger partners who take on late-stage development or market distribution. This is a key area to watch for announcements in late 2025 or early 2026.

Equity financing and capital raises to fund operations.

To be fair, this is the current, tangible revenue stream keeping the lights on. The company relies on issuing stock or debt instruments to cover its cash burn. The market valuation, as of October 31, 2025, was $8.23B with a stock price of $16.65. This high market capitalization, despite zero revenue, reflects the market's willingness to fund the pipeline via equity.

The market is definitely pricing in future success; the stock price has seen wild swings, for example, surging nearly 60,000% year-to-date at one point before a 38-for-1 stock split in June 2025.